-

A new chapter for Medisca: Sanjay D. Goorachurn appointed as Chief Executive Officer

MONTREAL--(BUSINESS WIRE)--Medisca, a global company specializing in personalized pharmaceutical solutions, is pleased to announce the appointment of Sanjay D. Goorachurn as the company’s new CEO, as founders, Tony Dos Santos and Maria Zaccardo, transition into strategic advisory roles as Chair and Vice Chair, respectively. Coinciding with the company’s 35th anniversary, this decision marks a significant milestone in Medisca’s history.

In 1989, Medisca opened its doors as a team of three with two products and a vision to bridge the gaps in patient care. Today, Medisca is a global leader in personalized medicine with more than 10 locations spanning 5 countries. Powered by a workforce of over 450 employees, Medisca offers a vast portfolio of more than 2,000 product solutions to meet the needs of diverse healthcare sectors.

“Over the course of 35 years, Medisca has seen remarkable development, grounded in its people and dynamic entrepreneurial culture,” said Dos Santos. “With the addition of Sanjay’s unique set of experiences and skillset, we are confident that this marks the beginning of a new chapter for Medisca.”

As a seasoned intellectual property lawyer with over 30 years of experience, Goorachurn is regarded as one of the world’s leading IP strategists working closely with senior executives of private and public companies on maximizing the commercial value of a company’s innovation and IP assets. It is Goorachurn’s distinct expertise and first-hand experience in implementing transformative growth for complex and global companies that drew Dos Santos and Zaccardo to him back in 2016, when he joined the Medisca team as a strategic advisor.

“Sanjay’s history with Medisca was an essential element that led to our decision to bring him on as our new CEO,” said Dos Santos. “Over the last 8 years, Sanjay has built authentic relationships with many Medisca people and coached us through some very successful wins, including the advancement and protection of our key innovations. It was critical to us that the company’s next CEO be someone who not only has the capability to take us forward, but also shares the same fundamental values that define who we are.”

“My goal is to preserve the entrepreneurial legacy of Tony and Maria and carry forward the company’s vision to empower personalized wellness for all,” said Goorachurn. “My focus will be centered around empowering Medisca’s people, creating a more structured infrastructure for strategic growth, building key partnerships, and continuing to leverage innovative excellence that sets Medisca apart, while expanding our global presence.”

About Medisca

Founded in 1989, Medisca is a global leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products completed by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, analytical testing, and more. Providing finely-tuned solutions to diverse wellness sectors across the globe, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.

Contacts

Medisca Communications
communications@medisca.com
1-800-665-6334

More News From Medisca

Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos

MONTREAL--(BUSINESS WIRE)--For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company's long-term strategy, with a focus on expanding Medisca's global reach, investing in new areas of growth, strengthening strategic partnerships, and continuing to advance the products, services, education, and expertise that healthcare professionals rely on every day. "When I founded Medisca, my vision was...

Medisca and dsm–firmenich Partner to Expand Access to Pharmaceutical-Grade Vitamin APIs for U.S. Compounding Market

MONTREAL--(BUSINESS WIRE)--Medisca, a global leader in personalized pharmaceutical medicine, has entered into a strategic partnership with dsm–firmenich, a leading ingredient manufacturer serving regulated pharmaceutical markets worldwide. Through this partnership, Medisca will make a portfolio of pharmaceutical-grade vitamin active pharmaceutical ingredients (APIs) available to U.S. compounding professionals, expanding access to ingredients manufactured within European cGMP environments and su...

Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 10,765,600, 11,090,224, 11,096,864, 10,231,903, and 10,993,876. The confidential settlement resolves the pending litigation. “This settlement validates the investment Medisca has made over the past decade in the MAZ innovation and technology,” said Sanjay Goorachu...
Back to Newsroom